Published Aug 12, 2026
AIM ImmunoTech Q2 2026: Enrollment Complete, Balance Sheet Repaired, and a Stock Priced at Its Cash
In-depth research on AIM covering the business overview, key financial moves, risk frame, and the bottom-line on what changed since the last report.
2,790 words12 min read
Read report